摘要
目的探讨非小细胞肺癌(NSCLC)患者血清可溶性CD105水平的变化及其在临床上的应用价值。方法采用酶联免疫吸附试验法(ELISA)检测65例NSCLC患者以及30例正常人血清可溶性CD105水平,并比较35例NSCLC患者手术前后血清可溶性CD105水平变化情况。结果NSCLC患者血清可溶性CD105水平明显高于正常对照组(P<0.01),血清可溶性CD105水平与临床分期有关、与NSCLC患者性别、年龄、病理类型无关,Ⅳ期NSCLC血清可溶性CD105水平明显高于其他各期(P<0.05～0.01),Ⅲ期明显高于Ⅱ期(P<0.01),Ⅱ期明显高于Ⅰ期(P<0.01),Ⅰ期与正常对照组比较,差异无统计学意义(P>0.05);手术后NSCLC患者血清可溶性CD105水平明显低于手术前(P<0.01)。结论血清可溶性CD105检测可能有助于指导NSCLC临床分期和治疗、判断预后。
Objective To investigate the changes of serum soluble CD105 in patients with non-small cell lung cancer（NSCLC） and its clinical value. Methods Enzyme linked immunosorbent assay（ELISA） were available to detect the level of serum soluble CD105 in 65 cases of patients with NSCLC and 30 cases of normal control subject,compared with 35 patients with NSCLC pre-and post-operation. Results The level of serum soluble CD105 were elevated in all subgroups of patients with NSCLC compared to the controls（P0.01）,serum soluble CD105 was correlated with clinical stage,and not with sex,age and pathologic types;the serum soluble CD105 level in stage Ⅳ was higher in comparison with stage Ⅲ,Ⅱand Ⅰ（P0.05~0.01）,in stage Ⅲ it was higher than in stage Ⅱ and Ⅰ（P0.05）,and in stage Ⅱ it was higher than in stageⅠ（P0.05）,but no significant difference was detected betweenⅠand normal control subject（P0.05）,that the serum soluble CD105 levels were remarkably reduced in patients with NSCLC after operation（P0.01）. Conclusions Detection of serum soluble CD105 may be recommended to direct Clinical stages,cancer therapy and predict prognosis of NSCLC.
出处
《齐齐哈尔医学院学报》
2012年第19期2589-2590,共2页
Journal of Qiqihar Medical University
